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Circulating PCSK9 destines low-density lipoprotein
receptor for degradation in lysosomes, resulting in
increased LDL cholesterol. Accordingly, it is an
attractive drug target for hypercholesterolemia, and
results from clinical trials are promising. While the
physiological role of PCSK9 in cholesterol meta-
bolism is well described, its complex mechanism of
action remains poorly understood, although it is
known to depend on intracellular trafficking. We
here identify sortilin, encoded by the hypercholester-
olemia-risk gene SORT1, as a high-affinity sorting re-
ceptor for PCSK9. Sortilin colocalizes with PCSK9 in
the trans-Golgi network and facilitates its secretion
from primary hepatocytes. Accordingly, sortilin-defi-
cient mice display decreased levels of circulating
PCSK9, while sortilin overexpression in the liver con-
fers increased plasma PCSK9. Furthermore, circu-
lating PCSK9 and sortilin were positively correlated
in a human cohort of healthy individuals, suggesting
that sortilin is involved in PCSK9 secretion in hu-
mans. Taken together, our findings establish sortilin
as a critical regulator of PCSK9 activity.
INTRODUCTION
High levels of circulating low-density lipoprotein cholesterol
(LDL-C) accelerate the progression of atherosclerosis, and the
lowering of LDL-C is currently considered the most effective
strategy in preventing coronary artery disease. Statins function
by inhibiting HMG-CoA reductase, the rate-limiting enzyme in
cholesterol synthesis, thereby elevating LDL receptor (LDLR)
expression to increase the uptake of LDL particles from the cir-
culation (Goldstein and Brown, 2009). However, some patients
are insensitive to statin treatment or experience serious adverse
effects. Furthermore, statins increase the expression of propro-310 Cell Metabolism 19, 310–318, February 4, 2014 ª2014 Elsevier Intein convertase subtilisin/kexin type 9 (PCSK9) (Awan et al.,
2012), a protein that targets LDLR for degradation in lysosomes
either following their encounter in the biosynthetic pathway or
by an extracellular mechanism, where secreted PCSK9 affects
hepatic LDLR levels (Costet et al., 2008; Lambert et al., 2012),
thereby counteracting the beneficial effects of statins. PCSK9
belongs to the superfamily of furin-like proprotein convertases
(Seidah et al., 2003), but the effect on LDLR degradation seems
to be independent of its proteolytic activity (McNutt et al., 2007).
However, the role of circulating PCSK9 in promoting hypercho-
lesterolemia is beyond dispute and strongly supported by pre-
clinical experiments and clinical trials where antibodies directed
against the LDLR binding site in PCSK9 effectively reduce LDL-C
levels (Roth et al., 2012; Stein et al., 2012).
Hepatocytes are the main source of circulating PCSK9
(Lagace et al., 2006). The same cell type also expresses high
levels of LDLR (Tavori et al., 2013), but the underlying mecha-
nism for how PCSK9 is escorted through the biosynthetic
pathway and what decides whether PCSK9 here destines
LDLR for degradation directly or continues to secretory vesicles
is at present enigmatic. PCSK9 is a soluble protein unable
to interact on its own with adaptor proteins coating the outer
surface of subcellular compartments. Furthermore, the effect
of PCSK9 on LDLR is independent of the LDLR intracellular
domain (Holla et al., 2010). Thus, the existence of PCSK9 sorting
receptors can be predicted. In support of this, the COPII adaptor
protein Sec24A is part of an unknown sorting receptor complex,
involved in the transfer of PCSK9 from the endoplasmic reticu-
lum (ER) to the cis-Golgi (Chen et al., 2013).
The sorting receptor sortilin belongs to the family of Vps10p-
domain receptors and has previously been linked to systemic
lipoprotein metabolism and risk of coronary artery disease
(Aulchenko et al., 2009; Kathiresan et al., 2008; Willnow et al.,
2011). The receptor family is characterized by the Vps10p
domain, consisting of a ten-bladed b-propeller that creates a
tunnel cavity for the binding of soluble ligands. In addition, the re-
ceptors contain a short cytoplasmic tail harboring recognition
motifs for subcellular sorting adaptor proteins. The functional
role of sortilin in lipoprotein metabolism is unclear, and several
mechanisms have been proposed (Kjolby et al., 2010; Musunuruc.
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Sortilin Is a PCSK9 Sorting Receptoret al., 2010; Willnow et al., 2011). Here, we identify sortilin as
a high-affinity receptor for PCSK9 and find that it interacts
with PCSK9 in the trans-Golgi network (TGN) of HepG2 cells.
PCSK9 displays altered subcellular localization, and its secretion
is hampered in sortilin knockout (KO) hepatocytes. Furthermore,
overexpression or KO of sortilin increases or decreases plasma
levels of PCSK9 in mice, respectively, suggesting that sortilin
facilitates the passage of PCSK9 through the late secretory
pathway.
RESULTS
Sortilin Is an Alternative PCSK9 Receptor
Similar to LDLR-related proteins, sortilin is a transmembrane
type I trafficking receptor with a putative role in lipoprotein meta-
bolism. Hence, we speculated if it might also be a PCSK9 target.
Using surface plasmon resonance (SPR), we found that PCSK9
bound to the immobilized extracellular domain of sortilin in a con-
centration-dependent manner with a dissociation constant (Kd)
of 6 nM at pH 7.4 (Figure 1A). For comparison, the reported Kd
of PCSK9 for LDLR is in the range of 120–620 nMat this pH (Cun-
ningham et al., 2007; Fisher et al., 2007), indicating that PCSK9
shows considerably higher affinity for sortilin than for LDLR.
We further tested the pH dependency of the interaction and
found it to be highly pH sensitive, as the binding was of high
affinity at physiological pH 7.4 and at slightly acidic pH 6.5,
whereas no interaction was observed at acidic pH 5.5 (Fig-
ure 1B). This stands in marked contrast to the interaction be-
tween PCSK9 and LDLR, which is strongly enhanced at acidic
pH (Cunningham et al., 2007; Fisher et al., 2007).
PCSK9 directs the LDLR and related receptors ApoER2,
VLDLR (Poirier et al., 2008), and LRP1 (Canuel et al., 2013)
for degradation in lysosomes. To assess if PCSK9 has this effect
on sortilin in hepatocyte-derived cells, we overexpressed
PCSK9 in HepG2 cells, which led to a marked reduction of
LDLR, while it had no effect on sortilin (Figures 1C and 1D). We
further incubated HepG2 cells with increasing concentrations
of PCSK9. While PCSK9 potently reduced the level of LDLR,
no change in sortilin levels was observed (Figures 1E and
1F). The combined results show that sortilin is an alternative
PCSK9 receptor, and that it, unlike LDLR and related receptors,
is insensitive to PCSK9-induced degradation.
To test if there is indeed an interaction between PCSK9 and
sortilin in cells, we performed coimmunoprecipitation (coIP)
experiments. Mature PCSK9 was preferentially pulled down
together with endogenous sortilin from cells transfected with a
construct encoding wild-type (WT) PCSK9 (Figure 1G). However,
the receptor could also pull down the proform of PCSK9 from
HepG2 cells overexpressing a propeptide cleavage-resistant
mutant (proPCSK9), suggesting that sortilin has the potential to
interact with both PCSK9 isoforms (Figure 1G).
Sortilin and PCSK9 Interact Late in the Secretory
Pathway
To study where in cells sortilin may encounter PCSK9, we
analyzed PCSK9-transfected HepG2 cells using confocal micro-
scopy. Interestingly, the bulk sortilin immunofluorescence (IF)
appeared to colocalize with PCSK9 in the paranuclear region,
whereas significantly less overlap between sortilin and mutantCell MproPCSK9 IF was observed (Figure 1H). This was reflected by
calculation of Pearson’s correlation coefficient (PCC), indicating
an overall correlation between sortilin and PCSK9 IF of 0.16 ±
0.02—significantly higher than for sortilin/proPCSK9 IF (PCC =
0.05 ± 0.02, p < 0.01). Mander’s colocalization coefficient
(MCC) of 63% ± 5.7% indicated that the majority of sortilin
IF overlapped with that of PCSK9. Significantly less overlap
between sortilin and mutant proPCSK9 IF was observed and
evident from a lower MCC of 34% ± 2.5% (p < 0.01).
We therefore compared the localization of sortilin with that of
subcellular markers. No colocalization was observed between
sortilin and the ER marker calnexin (PCC = 0.03 ± 0.05) or
the COPII vesicle marker Sec24A (PCC = 0.09 ± 0.03) (Fig-
ure 2A), rendering it unlikely that sortilin/PCSK9 complex forma-
tion occurs in the early secretory pathway. Sortilin displayed
some colocalization with the cis-Golgi marker GM130 (Fig-
ure 2A), as calculation of MCC revealed that 40% ± 6.8%
of GM130-positive structures contained sortilin, although their
overall IF did not correlate (PCC = 0.04 ± 0.03). Instead, we
observed clear colocalization with the trans-Golgi marker
TGN46 (Figure 2B), and the vast majority of TGN46-positive
structures were positive for sortilin (MCC = 82% ± 3.3%;
PCC = 0.22 ± 0.03). Partial colocalization between sortilin and
EEA1 was also observed (PCC = 0.14 ± 0.04), suggesting that
sortilin could play a role in PCSK9 endocytosis, but triple staining
indicated that several EEA1-positive structures containing
PCSK9 were devoid of sortilin (Figure 2C). These data suggest
that the sortilin and PCSK9 interaction is mainly established
late in the secretory pathway, such as the TGN, but could also
occur following endocytosis.
To confirm this hypothesis, we transfected HEK293 cells with
PCSK9 cDNA together with sortilin or mock cDNA and metabol-
ically labeled newly synthesized proteins with S35 cysteine and
methionine in the presence of brefeldin A, which inhibits protein
transport from the ER to the Golgi by preventing the formation of
COPII vesicles (Klausner et al., 1992). Following labeling, brefel-
din A was washed out, and PCSK9 was chased for the indicated
time periods (Figure 2D). In this experiment, the conversion of
proPCSK9 did not depend on sortilin (Figure 2E). Importantly,
coIP of labeled sortilin was not observed until 4 hr chase (Fig-
ure 2F), further substantiating that the complex does not form
in the ER or COPII vesicles.
Sortilin is also synthesized as a proprotein encompassing an
inhibitory propeptide that shields the Vps10p domain from ligand
binding until its removal in the TGN (Munck Petersen et al., 1999).
Importantly, PCSK9 binding was specifically inhibited by purified
sortilin propeptide (Figure 2G) but not by the peptide ligand
neurotensin (Figure 2H), demonstrating that the sortilin/PCSK9
interaction is not established prior to the TGN.
Sortilin Facilitates PCSK9 Secretion
We speculated that sortilin might regulate the extracellular levels
of PCSK9, either by sorting in the TGN or by endocytosis, andwe
therefore generated primary hepatocytes from WT and sortilin
KO (Sort1/) mice and measured the accumulation of PCSK9
in the media over a period of 18 hr (Figure 3A). Importantly,
PCSK9 secretion from KO hepatocytes was markedly attenu-
ated compared to WT cells, showing that sortilin predominantly
exerts its effects on PCSK9 in the secretory pathway. Thisetabolism 19, 310–318, February 4, 2014 ª2014 Elsevier Inc. 311
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Figure 1. Sortilin Is a High-Affinity PCSK9 Receptor
(A) PCSK9 (0.5–20 nM) bound to the extracellular domain of sortilin with high affinity (Kd = 6 nM), as determined using SPR.
(B) PCSK9 (20 nM) binding to sortilin is pH dependent, as binding was observed at pH 6.5–7.4 but lost at pH 5.5.
(C–F) PCSK9 does not induce degradation of sortilin. LDLR and sortilin in HepG2 cells were analyzed upon transfection with WT PCSK9 or mutant proPCSK9
encoding plasmids (C andD) or by incubation for 24 hr with purified PCSK9, as indicated (E and F).Western blots (WB) for GAPDHare included as loading controls.
Error bars indicate SEM; n = 3.Mutant proPCSK9 lead to a small reduction in LDLR,most likely caused by alternative processing. ***p < 0.001; **p < 0.01; *p < 0.05.
(G) WB showing coIP of PCSK9 with endogenous sortilin from HepG2 cells transfected with PCSK9, mutant proPCSK9, or mock plasmid, as indicated.
(H) HepG2 cells transfected with PCSK9 or proPCSK9 were stained for sortilin and PCSK9. The MCC of 63% ± 5.7% indicated that the majority of sortilin IF
overlapped with PCSK9. The correlation between sortilin and PCSK9 IF was 0.16 ± 0.02, as estimated by PCC. Significantly less overlap between sortilin and
mutant proPCSK9 IF was observed (MCC = 34%± 2.5%, p < 0.01 and PCC = 0.05 ± 0.02, p < 0.01. Nuclei (blue) are stained using Hoechst. Scale bars are 10 mm.
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Sortilin Is a PCSK9 Sorting Receptorobservation suggested altered subcellular localization of PCSK9
within hepatocytes of sortilin-deficient mice. Indeed, fraction-
ation of intracellular structures according to their density showed
a significant change in the subcellular localization of both PCSK9
isoforms in KO compared toWT liver tissue (Figure 3C). This was
evident from an increased concentration of proPCSK9 in frac-
tions of lower density (p < 0.01) and a reduction of mature
PCSK9 in sortilin KO in higher-density fractions (p < 0.05) (Fig-
ure 3D). We observed no change in the localization of albumin,
which is also secreted in a constitutive manner (Figure 3C).
We next measured PCSK9 in plasma from sortilin KO and WT
mice using ELISA and found that KOs had significantly lower
PCSK9 levels compared to WT (173 ± 15 ng/ml versus
242 ± 21 ng/ml; p < 0.01) (Figure 3B). This was accompanied
by a 2-fold increase in LDLR protein levels in KO compared to
WT liver samples (Figures 3F and 3G). Strikingly, adenoviral-
mediated overexpression of human sortilin (Avsort) in the liver
increased PCSK9 plasma concentration compared to control
virus (AvLacZ) (406 ± 41 ng/ml versus 254 ± 28 ng/ml; p <
0.01) (Figure 3E). The increase in circulating PCSK9 was accom-
panied by a 27% ± 8.4% (p < 0.05) reduction in hepatic LDLR
(Figures 3H and 3I). Together, these data suggest that sortilin
plays a critical role in escorting PCSK9 to constitutive secretory
vesicles of hepatocytes with concomitant effect on LDLR in vivo.
Circulating PCSK9 Correlates with Sortilin in Humans
We compared the expression of sortilin and LDLR in hepatic tis-
sues from human and mouse. Both species were found to have
levels of sortilin corresponding to25% of LDLR, as determined
by qPCR analysis (Figure 4A). Sortilin is constitutively released
from the cell surface following shedding by metalloproteinases
(Hermey et al., 2006) and can therefore be detected in human
serum, serving as a proxy for receptor expression in tissues (Har-
ris et al., 2012). Once released from the cell surface, sortilin does
not influence PCSK9 activity, as we observed no changes in
extracellular PCSK9-induced downregulation of LDLR regard-
less of the presence of excess sortilin extracellular domain (Fig-
ures 4B and 4C). Based on ourmouse experiments, it is tempting
to speculate that altered sortilin levels might correlate with a
change in circulating PCSK9 in human subjects. To this end,
we developed a sandwich ELISA for soluble sortilin using sorti-
lin-specific antibodies for capture and detection (Figure 4C),
quantified sortilin in serum obtained from healthy individuals ofFigure 2. PCSK9 and Sortilin Colocalize in the TGN
(A) HepG2 cells stained for sortilin and subcellular markers. The PCCswere calcula
Sec24A, and GM130, respectively. A minor fraction of sortilin colocalized w
compartments contained sortilin IF. Nuclei (blue) are stained using Hoechst. Sca
(B) HepG2 cells stained for sortilin and TGN46, showing clear overlap of sortilin IF
also positive for sortilin. The PCC for sortilin/TGN46 was 0.224 ± 0.028, significa
(C) Triple staining of HepG2/PCSK9 cells for EEA1, sortilin, and PCSK9; arrowhea
for sortilin. The PCC for sortilin/EEA1 IF was 0.14 ± 0.04.
(D–F) Metabolic labeling and IP of PCSK9 from transfected HEK293. This cell line
lysate at indicated time points were visualized by phosphorimaging (D), quantified
0 hr (errors bars indicate SEM) (E). CoIP of labeled sortilin with PCSK9 is observ
(G) PCSK9 (20 nM) binding to sortilin is inhibited by the sortilin propeptide (propep
propep (200–700 s) where after a new injection of propep was performed in the ab
propep + PCSK9). Buffer alone was injected in the third flow channel at 200 s and P
response difference between flow channels 1 and 2 to that of PCSK9 in flow cha
(H) PCSK9 (20 nM) binding to sortilin is not inhibited by coinjection with the neur
314 Cell Metabolism 19, 310–318, February 4, 2014 ª2014 Elsevier Inmixed age and gender, and compared it to their serum levels
of PCSK9. Indeed, we found a significant positive correlation be-
tween sortilin and PCSK9 (r = 0.22; p < 0.05; n = 79) (Figure 4D),
suggesting that sortilin expression affects circulating PCSK9
levels in humans. For comparison, the correlation factor for
PCSK9 and LDL-C is r = 0.24 (Lakoski et al., 2009).
DISCUSSION
PCSK9 was discovered 10 years ago, and soon after, its role in
LDL metabolism became clear. It is now well established that
PCSK9 destines LDLR for lysosomal degradation following their
encounter in the secretory pathway (Poirier et al., 2009) or at the
cell surface (Lagace et al., 2006). It is less clear how this function
is executed, as PCSK9 is a soluble protein without apparent pro-
teolytic activity. Strikingly, the pH optimum for LDLR/PCSK9
binding is pH 5.5, approximately the pH of secretory vesicles
and late endosomes. For comparison, the pH in ER, Golgi, and
early endosomes is around 7.2, 6.5, and 6.3, respectively (Casey
et al., 2010). In this pH range, PCSK9 shows only modest affinity
for LDLR (Cunningham et al., 2007; Fisher et al., 2007). It is there-
fore tempting to speculate that the route of PCSK9 through the
biosynthetic pathway or endosomal system depends on its inter-
action with transmembrane sorting receptors other than LDLR.
Many of the loss-of-function mutations in PCSK9 are in fact
related to its defective passage through the secretory pathway
(Nassoury et al., 2007). As such, the exit of PCSK9 from ER de-
pends on the intracellular adaptor Sec24A (Chen et al., 2013),
suggesting a regulatory point in the early secretory pathway. Sol-
uble proteins can undergo concentrative transport in the early
biosynthetic pathway mediated by specialized groups of recep-
tors releasing the cargo into the cis-Golgi compartment. Specific
ER-residing sorting receptors enable soluble cargo to move
faster through ER and Golgi, in contrast to the slower receptor-
independent bulk flow pathway (Dancourt and Barlowe, 2010).
At present, the identity of the PCSK9-specific ER sorting
receptor is unknown. However, our results suggest that sortilin
provides an additional regulatory step of PCSK9 secretion in
the late secretory pathway, likely by facilitating the transport of
PCSK9 from the TGN to the plasma membrane. The TGN is
the main intracellular sorting hub, and soluble proteins may
here interact with transmembrane receptors, directing them to
their cellular destination (De Matteis and Luini, 2008). We findted to0.03 ± 0.05,0.09 ± 0.03, and0.04 ± 0.03 for sortilin IF with calnexin,
ith GM130 (MCC = 3.6% ± 0.9%), while 40% ± 6.8% of GM130-positive
le bars are 10 mm.
with TGN46 (MCC = 28% ± 5.5%). Furthermore, 82% ± 3.3% of TGN46 IF was
ntly higher than that of sortilin/GM130 (p = 2.4 3 106).
ds indicate structures positive for EEA1 and PCSK9 staining, but with no signal
expresses very low levels of endogenous sortilin. ProPCSK9 and PCSK9 in cell
by densitometry, and normalized with respect to the protein levels at time point
ed in sortilin-transfected cells from time point 4 hr (F).
) (10 mM). The SPR chip was first saturated by injecting two flow channels with
sence (flow channel 1, propep + propep) or presence of PCSK9 (flow channel 2,
CSK9 alone at 700 s. The degree of inhibition was estimated by comparing the
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Figure 4. PCSK9 and Sortilin Levels Correlate in Humans
(A) Quantitative RT-PCR analysis of SORT1 and LDLRmRNA in human and of
Sort1 and Ldlr mRNA in mouse liver tissue. Expression in percentage of the
b-actin gene (ACTB or Actb), with error bars indicating SD; n = 4.
(B and C) Soluble sortilin does not influence PCSK9 activity. WB showing the
LDLR level in HepG2 cells incubatedwith 100 nMPCSK9 ± sortilin extracellular
domain (B). Bar graph shows mean LDLR levels relative to untreated cells
(error bars indicate SEM; n = 3) (C).
(D) Positive correlation between PCSK9 and sortilin in human serum, as
measured by ELISA. Spearman correlation coefficient r = 0.22; p < 0.05; n = 79.
Mean levels were 229 ± 63 ng/ml and 23 ± 6.1 ng/ml for PCSK9 and sortilin,
respectively.
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Sortilin Is a PCSK9 Sorting Receptorthat sortilin and PCSK9 colocalize in the TGN of HepG2 cells and
that the presence of sortilin is important for secretion of PCSK9
from primary hepatocytes. Strikingly, lack of sortilin or viral over-
expression has marked impact on circulating PCSK9 levels with
concomitant effect on the levels of hepatic LDLR. This effect is
most likely solely posttranslational, as altered sortilin expression
in mice has no effect on the transcription of the Pcsk9 or Ldlr
genes (Kjolby et al., 2010). In analogy, the cardiovascular pheno-
type of sortilin KOmice reported by Kjolby et al. (2010) is charac-
terized by marked reduction specifically in LDL-C and not inFigure 3. Sortilin Facilitates PCSK9 Secretion
(A) ELISA measurements of PCSK9 secreted into the media of primary hepatocy
changed (t = 0 hr), and the fresh conditioned mediumwas subsequently harvested
PCSK9 level at t = 1 hr for each genotype (n = 4).
(B) WB showing the expression of PCSK9, sortilin, and GAPDH in lysates of WT
(C and D) Intracellular compartments of WT and KO liver homogenates (each a
gradient centrifugation, and fractions were analyzed byWB. Fraction numbers inc
results. Bar graphs show densitometry quantification of proPCSK9 and PCSK9 i
(E) PCSK9 levels measured by ELISA in plasma obtained fromWT and Sort1/m
with adenovirus encoding sortilin (Avsort) (n = 4) or LacZ (AvLacZ) (n = 5).
(F and G) WB of LDLR in liver homogenates from WT and Sort1/mice (F). Contr
band intensities normalized with respect to the LDLR level in WT mice (n = 12/ge
(H and I) WB of LDLR in liver homogenates from WT mice with adenovirus-media
samples is shown as control. The bar graph (I) shows quantification of band inten
Error bars indicate SEM. ***p < 0.001, **p < 0.01, and *p < 0.05.
316 Cell Metabolism 19, 310–318, February 4, 2014 ª2014 Elsevier Inother lipoprotein particles, while sortilin overexpression specif-
ically increases LDL-C. Using a different sortilin KO model,
another group reported severe hypercholesterolemia (Musunuru
et al., 2010), but this was later questioned in Strong et al. (2012),
who stated that Sort1-deficient mice are not hypercholesterol-
emic. Musunuru et al. (2010) also reported that massive sortilin
overexpression in the liver reduced LDL-C. Our present data
show that a more modest sortilin overexpression results in
increased plasma PCSK9, in line with the findings in Kjolby
et al. (2010). However, it cannot be excluded that, at very high
levels, sortilin may start to play a dominating role in the clearance
of LDL and even of PCSK9.
The strongest interaction between sortilin and PCSK9 is at pH
6.5, while binding was completely lost at pH 5.5. These data fit
with a role for sortilin in binding PCSK9 in the TGN (pH 6.5)
and releasing it in secretory vesicles (pH 5.5), thereby serving
to concentrate the PCSK9 flow into constitutive secretory vesi-
cles. As a consequence, the subcellular localization of PCSK9 is
altered in sortilin KOs, and its secretion is hampered in KO hepa-
tocytes. In a similarmanner, sortilin has also been shown to assist
the secretion of interferon-g from T cells (Herda et al., 2012) and
ApoB100 from hepatocytes (Kjolby et al., 2010). In this regard, it
is curious thatPCSK9andApoB100are foundcirculating together
in a complex (Sun et al., 2012) and that a gain-of-function PCSK9
mutant dramatically increases ApoB100 secretion (Sun et al.,
2005). Thus, PCSK9 may be a contributing factor to the physical
link between sortilin and ApoB100.
There is a strong link between PCSK9 and LDL metabolism
in humans, as exemplified in large population-based studies
showing a positive correlation between PCSK9, LDL-C, and
increased risk of coronary artery disease (Awan et al., 2012;
Cohen et al., 2006; Lakoski et al., 2009). Interestingly, we here
also find a positive correlation between circulating PCSK9 and
sortilin in a human cohort, indicating a link between sortilin levels
and PCSK9 secretion in the general population. Hence, our
findings show that sortilin is a regulator of PCSK9 secretion
and could suggest that therapeutic targeting of this interaction
may modulate circulating PCSK9 levels.
EXPERIMENTAL PROCEDURES
Immunofluorescence
Cells were fixed in 4% PFA and permeabilized using 0.1% Triton X-100 before
incubation with primary antibodies and fluorescent secondary antibodies
(Invitrogen). Nuclei were visualized with Hoechst dye (Sigma Aldrich). Imagestes derived from sortilin KO or WT mice. After 4 hr in culture, the medium was
at the time points indicated. PCSK9 levels were normalized with respect to the
and KO hepatocytes.
pool of three animals) were separated according to their density by sucrose
rease with increasing density. The fractionation was repeated twice with similar
n each fraction. Results were evaluated by two-way ANOVA.
ice (n = 12 of each genotype) and fromWTmice 14 days following the injection
ol WBs of sortilin and b-actin are shown. Bars (G) show quantification of LDLR
notype).
ted overexpression of sortilin (H). Expression of sortilin, LacZ, and GAPDH in
sities, normalized with respect to the LDLR levels in AvLacZ-injected animals.
c.
Cell Metabolism
Sortilin Is a PCSK9 Sorting Receptorwere acquired on a Zeiss LSM780. Colocalization analysis was carried out
using Zen 2011, and at least 300 cells were examined for each antibody com-
bination in three independent experiments.
Metabolic Labeling of Cellular Proteins
Newly synthesized proteins of human embryonic kidney (HEK293) cells trans-
fected with PCSK9 cDNA together with sortilin or mock cDNA were metabol-
ically labeled with 200 mCi/ml S35-Cys/S35-Met (Pro-mix; GE Healthcare) in
Dulbecco’s modified Eagle’smedium (DMEM) without Cys/Met supplemented
with 2% dialyzed FBS and brefeldin A (10 mg/ml; Pierce) for 4 hr at 37C.
Following labeling, brefeldin A was washed out, and cells were incubated in
DMEM with 2% FBS. At defined time points, cell lysates were harvested and
subjected to IP using 0.5 mg anti-PSCK9. Precipitated proteins were visualized
by phosphorimaging after SDS-PAGE.
Sortilin and PCSK9 in Human Serum
Human serum samples were part of the Danish PRISME study and obtained
from employees within public service workplaces (Kaerlev et al., 2011). Sam-
ples from 79 subjects of mixed gender and age were analyzed. None of the
subjects had any reported use of cholesterol-lowering agents (e.g., statins).
PCSK9 and sortilin were determined using ELISA. GraphPad Prism version
6.0 was used for nonparametric test for significant correlation. All experiments
using human samples were performed according to national and institutional
guidelines.
Statistics
Unless otherwise indicated, results were evaluated using Student’s t test,
and error bars indicate SEM. Statistical significant p values are indicated by
asterisks: *p < 0.05, **p < 0.01, and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.
2013.12.006.
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